Harold Davidson & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.72M Buy
4,767
+97
+2% +$99.1K 2.48% 10
2026
Q1
$4.3M Buy
4,670
+13
+0.3% +$13.2K 2.09% 13
2025
Q4
$5M Buy
4,657
+58
+1% +$55.5K 2.21% 12
2025
Q3
$3.51M Buy
4,599
+1,417
+45% +$1.05M 1.59% 16
2025
Q2
$2.48M Sell
3,182
-902
-22% -$701K 1.61% 15
2025
Q1
$3.37M Buy
4,084
+42
+1% +$34.9K 1.84% 14
2024
Q4
$3.12M Buy
+4,042
New +$3.35M 1.49% 19

Other funds holding LLY

Harold Davidson & Associates's LLY Position: Q2 2026 in Review

Harold Davidson & Associates increased its Eli Lilly (LLY) stake by 2.1% in Q2 2026, buying an estimated $99.1K and bringing the position to 4,767 shares worth $5.72M. The position accounts for 2.48% of the portfolio, ranked #10.

Harold Davidson & Associates first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Harold Davidson & Associates held 4,767 shares of Eli Lilly worth $5.72M as of Q2 2026.
  • Harold Davidson & Associates bought 97 Eli Lilly shares in Q2 2026, an estimated $99.1K.
  • Eli Lilly made up 2.48% of Harold Davidson & Associates's portfolio in Q2 2026, its #10 holding.
  • Harold Davidson & Associates first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Harold Davidson & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.